Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion

Zheng, Runhui; Chen, Xiaobo; Wang, Chunyan; Qin, Pengfei; H, Tan; Luo, Xiaodan

doi:10.1155/2020/8879448

Cited by 8 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, sintilimab was also reported to be used in a human immunodeficiency virus-infected r/r cHL patient, with a satisfying efficacy and mild, acceptable toxicities (34). In diffuse large B-cell lymphoma, a triple combination of decitabine, sintilimab plus a histone deacetylase inhibitor chidamide achieved partial remission (PR) (35).…”

Section: Efficacy Of Sintilimab In Lymphomamentioning

confidence: 99%

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

et al. 2020

View full text Add to dashboard Cite

Sintilimab (Tyvyt®) is a monoclonal antibody against programmed cell death protein 1 (PD-1). It could block the interaction between PD-1 and its ligands and help the anti-tumor effect of T-cells to recover. Sintilimab is developed by Innovent Biologics and Eli Lilly and Company and has been approved to treat relapsed or refractory classical Hodgkin lymphoma in patients who have undergone two or more lines of systemic chemotherapy by the National Medical Products Administration of China. Recently, sintilimab has been reported in plenty of literature and shows satisfying anti-tumor effect. Meanwhile, there are some reports showing its side effects. Overall, sintilimab has similar anti-tumor effects and a better safety profile compared to nivolumab and pembrolizumab in Hodgkin lymphoma, natural killer/T cell lymphoma and advanced non-small cell lung cancer. In this review, we aim to briefly describe the mechanisms, pharmacological characteristics, anti-tumor effects, predictive parameters of efficacy and side effects of sintilimab, providing valuable information of sintilimab for decision-making in the treatment of tumors in the future.

show abstract

Section: Efficacy Of Sintilimab In Lymphomamentioning

confidence: 99%

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Application of triplet therapy of sintilimab with decitabine and GDP (gemcitabine, DDP, and dexamethasone), enhanced clinical responses in a diffuse large B-cell lymphoma (DLBCL) patient with 17p deletion who was irresponsive to the 1st and the 2nd line treatments [ 11 ].…”

Section: Clinical Progress Of Sintilimab In Applicationmentioning

confidence: 99%

Recent updates on Sintilimab in solid tumor immunotherapy

Liu

2020

Biomark Res

View full text Add to dashboard Cite

In recent years, there have been advancements in traditional patterns of tumor therapy with the adoption of immunotherapy. Its application with or without other combined regimens has attracted attention from clinicians. Sintilimab (Tyvyt®), a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. Sintilimab has been proven to be clinically beneficial in multiple solid tumor therapies. Combination therapy and monotherapy have shown potential and encouraging anti-tumor efficacy with controllable and acceptable toxicities. The combination therapy is more likely to be a novel and promising therapeutic option. This study provides an overview of the status of sintilimab-based clinical trials in various solid tumors.

show abstract

“…Certainly, as mentioned above, some conclusions about the clinical application of ICIs and HDACi are currently based mostly on single cases and their therapeutic efficacy is subject to uncertainty ( 47 , 48 ). Additional clinical trials and cohort studies of drugs in hematological tumors need to be conducted and validated.…”

Section: Discussionmentioning

confidence: 99%

Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis

Zhao

Deng²,

Jiang³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Histiocytic sarcoma (HS) is a rare hematological malignancy with limited treatment options, and it is also prone to complications such as hemophagocytic lymphohistiocytosis (HLH) in the later stages of the disease, leading to difficulties in treatment and poor prognosis. It highlights the importance of developing novel therapeutic agents. Herein, we present a case of a 45-year-old male patient who was diagnosed with PD-L1-positive HS with HLH. The patient was admitted to our hospital with recurrent high fever, multiple skin rashes with pruritus throughout the body and enlarged lymph nodes. Subsequently, pathological biopsy of the lymph nodes revealed high expression of CD163, CD68, S100, Lys and CD34 in the tumor cells and no expression of CD1a and CD207, confirming this rare clinical diagnosis. Concerning the low remission rate by conventional treatment in this disease, the patient was administered with sintilimab (an anti-programmed cell death 1 [anti-PD-1] monoclonal antibody) at 200 mg/d combined with a first-line chemotherapy regimen for one cycle. Further exploration of pathological biopsy by using next-generation gene sequencing led to the use of targeted therapy of chidamide. After one cycle of combination therapy (chidamide+sintilimab, abbreviated as CS), the patient achieved a favorable response. The patient showed remarkable improvement in the general symptoms and laboratory examination results (e.g., elevated indicators of inflammation); even the clinical benefits was not persistent, he survived one more month after his cessation of treatment by himself due to economic difficulty. Our case suggests that PD-1 inhibitor coupled with targeted therapy might constitute a potential therapeutic option for primary HS with HLH.

show abstract

Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion

Cited by 8 publications

References 26 publications

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

Recent updates on Sintilimab in solid tumor immunotherapy

Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis

Contact Info

Product

Resources

About